AstraZeneca Annual Report and 130 Form 20-F Information 2005 ADDITIONAL INFORMATION FOR US INVESTORS INTRODUCTION Capitalisation of interest New accounting standards adopted The accompanying consolidated Financial AstraZeneca does not capitalise interest under AstraZeneca has adopted the provisions of SFAS Statements included in this Annual Report IFRS.
US GAAP requires interest incurred No.
123 R Share-Based Payment in 2005. are prepared in accordance with IFRS as as part of the cost of constructing property, SFAS No.
123 R requires compensation cost adopted by the EU.
There are certain significant plant and equipment to be capitalised and related to share-based payments to be recognised differences between IFRS and US GAAP amortised over the life of the asset.
AstraZeneca has which affect AstraZenecas net income and followed the transitional arrangements for shareholders equity and, on pages 130 to Deferred taxation modified retrospective application in adopting 136, additional information under US GAAP Under IFRS, full provision for deferred taxation SFAS No.
123 R. As a consequence, the is set out as follows: is made although there are a number of 2004 comparative US GAAP income before different bases from US GAAP on which this tax has been reduced by $147m with a related Summary of differences between IFRS and calculation is made: for example, the elimination tax credit of $58m and the shareholders US GAAP accounting principles: page 130. of intra-group profit on inventories and shareequity at 31 December 2004 increased by Net income: page 131. based payment transactions.
The impact in 2003 was to reduce US GAAP condensed consolidated is provided on a full liability basis under US GAAP, income before tax by $154m with a related tax statement of operations: page 131. which requires deferred tax assets to be credit of $23m and increase shareholders US GAAP statement of comprehensive recognised without a valuation allowance equity at 31 December 2003 by $105m.
income: page 132. if their realisation is considered to be more Stock-based compensation: page 132. likely than not.
New accounting standards not adopted Pension and post-retirement benefits: In November 2004, the FASB issued SFAS page 132.
Pension and post-retirement benefits No.
151 Inventory Costs to clarify the Taxation: page 134.
IFRS requires that in respect of defined benefit accounting for abnormal amounts of idle Shareholders equity: page 135. plans, obligations are measured at discounted facility expense, freight, handling costs and Acquired intangible assets and goodwill: fair value whilst plan assets are recorded at fair wasted material spoilage.
The operating and financing costs of is effective for inventory costs incurred during US GAAP condensed consolidated such plans are recognised separately in the fiscal years beginning after 15 June 2005. statement of cash flows: page 136. income statement: service costs are spread The adoption of SFAS No.
151 is not expected systematically over the lives of employees and to have a material effect on the results or net DIFFERENCES BETWEEN INTERNATIONAL financing costs are recognised in the periods assets of AstraZeneca.
AND US ACCOUNTING PRINCIPLES in which they arise.
US GAAP adopts a similar Purchase accounting adjustments approach.
Under IFRS, actuarial gains and In December 2004, the FASB issued SFAS Under IFRS, the merger of Astra and Zeneca losses are permitted to be recognised No.
152 Accounting for Real Estate Timeis accounted for as a merger of equals poolingimmediately in the statement of recognised sharing Transactions, an amendment of FASB of-interests as a result of the business income and expense.
Under US GAAP, such Statements No.
66 and 67 which provides that combinations exemption permitted by IFRS 1 actuarial gains and losses are permitted to real estate time-sharing transactions should First-time Adoption of International Financial be amortised on a straight-line basis over the be accounted for as non-retail land sales.
Under US GAAP the average remaining service period of employees.
152 is effective for fiscal years beginning merger was accounted for as the acquisition A minimum pension liability is also recognised after 15 June 2005.
The adoption of SFAS of Astra by Zeneca using purchase accounting.
through other comprehensive income in No.
152 is not expected to have a material effect Under purchase accounting, the assets and certain circumstances when there is a deficit on the net assets or results of AstraZeneca.
liabilities of the acquired entity are recorded of plan assets relative to the accumulated at fair value.
As a result of the fair value benefits obligation.
In December 2004, the FASB issued SFAS exercise, increases in the values of Astras No.
153 Exchanges of Non-monetary Assets, property, plant and equipment and inventory Intangible assets an amendment of APB Opinion No.
29 which were recognised and values attributed to its Under IFRS, certain payments for rights replaces the current exception from fair value in-process research and development and to compounds in development are capitalised.
measurement for non-monetary exchanges existing products, together with appropriate Under US GAAP, these payments are of similar productive assets with a general deferred taxation effects.
The difference between generally expensed.
exception from fair value measurement for the cost of investment and the fair value of the exchanges of non-monetary assets that do assets and liabilities of Astra was recorded as Financial instruments and hedging activities not have commercial substance.
The amount allocated to in-process Under IFRS, certain financial assets and certain shall be applied prospectively and is effective research and development was, as required financial liabilities including derivatives are for non-monetary asset exchanges occurring by US GAAP, expensed immediately in the first recognised at fair value: movements in the fair in fiscal periods beginning after 15 June 2005. reporting period after the business combination.
value may be recorded in equity or through The adoption of SFAS No.
153 is not expected Fair value adjustments to the recorded amount income, depending upon their designation.
to have a material effect on the results or net of inventory were expensed in the period the Under US GAAP, marketable securities are assets of AstraZeneca.
Additional amortisation recognised at fair value, with movements in fair and depreciation have also been recorded in value taken to a separate component of equity.
In May 2005, the FASB issued SFAS No.
154 respect of the fair value adjustments to tangible Derivatives are also measured at fair value with Accounting Changes and Error Corrections and intangible assets.
However, a replacement of APB Opinion No.
20 and FASB financial liabilities are recorded at amortised cost.
154 requires Under IFRS, up until 31 December 2002, retrospective application of prior periods goodwill was required to be capitalised and financial statements for changes in accounting amortised.
154 applies to accounting is tested annually for impairment but not periods beginning after 15 December 2005. amortised.
Under US GAAP, there is an The adoption of SFAS No.
154 is not expected equivalent requirement, but the effective to have a material effect on the results or net date was 1 January 2002. assets of AstraZeneca.
Additional Information for US Investors 131 NET INCOME As a result of the significant difference between the IFRS and US GAAP treatment of the combination of Astra and Zeneca in the year of acquisition, and in the results of preceding periods, condensed statements of operations and cash flow under US GAAP have been prepared for the benefit of US investors.
The following is a summary of the adjustments to net income and shareholders equity which would have been required if US GAAP had been applied instead of IFRS.
2004 2003 2005 restated restated $m $m $m Net income for the period under IFRS 4,706 3,664 3,022 Adjustments to conform to US GAAP Purchase accounting adjustments including goodwill and intangibles Deemed acquisition of Astra Amortisation and other acquisition adjustments 1,019 1,014 952 Others Capitalisation, less disposals and amortisation of interest 13 1 17 Deferred taxation On fair values of Astra 283 283 266 Others 65 55 178 Pension and other post-retirement benefits expense 74 52 23 Financial instruments 35 61 1 In-licensed development intangibles 29 46 21 Deferred income recognition 14 Unrealised losses on foreign exchange and others 13 Net income in accordance with US GAAP 3,884 2,951 2,149 Restated in respect of SFAS 123 R US GAAP CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS 2004 2003 2005 restated restated For the years ended 31 December $m $m $m Sales 23,950 21,426 18,849 Cost of sales 5,356 5,152 4,471 Distribution costs 211 177 162 Research and development 3,429 3,900 3,493 Selling, general and administrative expenses 8,783 8,003 7,036 Amortisation of intangibles 1,009 953 881 Other income 193 534 225 Operating income 5,355 3,775 3,031 Net interest income expense 123 1 63 Income from continuing operations before taxation 5,478 3,774 3,094 Taxes on income from continuing operations 1,594 823 945 Net income from continuing operations 3,884 2,951 2,149 Net income for the year 3,884 2,951 2,149 Weighted average number of $0.25 Ordinary Shares in issue millions 1,617 1,673 1,709 Dilutive impact of share options outstanding millions 1 23 Diluted weighted average number of $0.25 Ordinary Shares in accordance with US GAAP millions 1,618 1,675 1,712 Net income per $0.25 Ordinary Share and ADS in accordance with US GAAP basic and diluted $2.40 $1.76 $1.26 Restated in respect of SFAS 123 R AstraZeneca Annual Report and 132 Form 20-F Information 2005 ADDITIONAL INFORMATION FOR US INVESTORS CONTINUED US GAAP STATEMENT OF COMPREHENSIVE INCOME 2004 2003 2005 restated restated For the years ended 31 December $m $m $m Net income for the year 3,884 2,951 2,149 Exchange losses gains, net of tax 3,279 2,106 3,635 Other movements, net of tax 218 20 81 Total comprehensive income 823 5,077 5,703 Restated in respect of SFAS 123 R Other movements in 2005 include a reduction in the minimum liability under SFAS No.
87 Employers Accounting for Pensions from $253m to $36m.
Tax effects on exchange gains losses were $ 46 m and on other movements $61m.
The cumulative exchange gains and losses net of tax on the translation of foreign currency financial statements under US GAAP are set out in the following note: 2004 2003 2005 restated restated For the years ended 31 December $m $m $m Balance at 1 January 4,342 2,236 1,399 Movement in year 3,279 2,106 3,635 Balance at 31 December 1,063 4,342 2,236 Restated in respect of SFAS 123 R The cumulative total of other movements net of tax at 31 December 2005 was a credit of $84m 2004 charge of $134m, 2003 charge of $154m.
STOCK-BASED COMPENSATION The Group has adopted SFAS No.
123 R Share-Based Payments in the year under review in respect of share options granted and has applied its provisions retrospectively.
The effects on income from continuing operations, income before tax, net income and basic and diluted earnings per share are set out in the table below.
There were no impacts from adoption on the cash flows of the Group.
2005 2004 2003 For the years ended 31 December $m $m $m Income from continuing operations 128 147 154 Income before tax 128 147 154 Net income 100 107 111 Earnings per $0.25 Ordinary Share and ADS in accordance with US GAAP basic and diluted $0.06 $0.06 $0.06 The total compensation cost for nonvested awards not yet recognised at 31 December 2005 was approximately $137m and is expected to be recognised over a weighted average period of 21 months.
$143m was received during 2005 from the exercise of share options and similar instruments granted under share-based payment arrangements and $3.9m tax benefit was realised from share options exercised during the year.
PENSION AND POST-RETIREMENT BENEFITS For the purposes of US GAAP, the pension information as set out in Note 23 in respect of the UK retirement plans and of the retirement plans of the non-UK subsidiaries has been restated in the following tables in accordance with the requirements of SFAS No.
132 Employers Disclosures about Pensions and Other Postretirement Benefits, an amendment of FASB Statements No.
These plans comprise substantially all of the actuarial liabilities of all AstraZeneca retirement plans.
The changes in projected benefit obligations, plan assets and details of the funded status of these retirement plans, together with the changes in the accumulated other post-retirement benefit obligations, under SFAS No.
132 are as follows: Pension benefits Other post-retirement benefits 2005 2004 2003 2005 2004 2003 Change in projected benefit obligation $m $m $m $m $m $m Benefit obligation at beginning of year 8,707 7,416 5,943 249 242 210 Service cost 256 229 171 12 11 9 Interest cost 419 385 329 14 14 14 Participant contributions 31 30 26 1 11 Actuarial loss gain 764 328 545 1 3 24 Settlement and curtailment 10 5 Benefits paid 305 281 245 15 18 19 Exchange 825 590 642 3 23 Benefit obligation at end of year 9,047 8,707 7,416 257 249 242 Additional Information for US Investors 133 PENSION AND POST-RETIREMENT BENEFITS CONTINUED Pension benefits Other post-retirement benefits 2005 2004 2003 2005 2004 2003 Change in plan assets $m $m $m $m $m $m Fair value at beginning of year 6,972 5,905 4,549 217 195 133 Actual return on plan assets 1,134 565 590 13 22 35 Group contribution 165 280 489 13 17 43 Participant contributions 31 30 26 1 1 Benefits paid 305 281 245 15 17 17 Exchange 629 473 496 1 Fair value of plan assets at end of year 7,368 6,972 5,905 230 217 195 Funded status of plans 1,679 1,735 1,511 27 32 47 Unrecognised net loss 1,420 1,644 1,503 32 29 36 Prior service cost not recognised 25 15 25 8 11 9 Unrecognised net obligation on implementation 1 1 19 25 29 234 77 16 16 11 9 Adjustments to recognise minimum liability: Intangible assets 36 39 Accumulated other comprehensive income 36 217 260 Accrued benefit liability asset 270 330 283 16 11 9 At 31 December 2005, the projected benefit obligation, accumulated benefit obligation and fair value of the plan assets in respect of the pension plans above with accumulated benefit obligations in excess of plan assets were $6,984m, $5,990m and $5,566m, 2004 $6,699m, $5,800m and $5,220m respectively.
The total of accumulated benefit obligations for the pension plans was $7,965m 2004 $7,443m.
The measurement date for the plan assets and benefit obligations set out above was 31 December 2005.
Contributions to the plans in 2006 are estimated to be $163m.
Following an employee vote in December 2005, and subject to regulatory approval, the Japanese defined benefit pension scheme is to be closed and its assets and obligations transferred to a defined contribution scheme.
The curtailment and settlement cost, to be recognised in 2006, will be approximately $35m and the cash payment in the region of $100m.
Assumed discount rates and rates of increase in remuneration used in calculating the projected benefit obligations together with long term rates of return on plan assets vary according to the economic conditions of the country in which the retirement plans are situated.
The weighted average rates used for calculation of year end benefit obligations and forecast benefit cost in the retirement plans and other benefit obligations for SFAS No.
132 purposes were as follows: Pension benefits Other post-retirement benefits 2005 2004 2003 2005 2004 2003 % %% % %% Discount rate 4.8 5.2 5.5 5.4 5.7 5.9 Long term rate of increase in remuneration 3.8 3.9 4.0 n a n a n a Expected long term return on assets 6.4 6.8 6.6 6.5 7.8 7.8 The Group has assumed a long term rate of increase in healthcare costs of 9.9%, reducing to 4.9%.
Pension benefits Other post-retirement benefits 2005 2004 2003 2005 2004 2003 $m $m $m $m $m $m Net periodic cost Service cost present value of benefits accruing during the year 256 229 171 12 11 9 Interest cost on projected benefit obligations 419 385 329 14 14 14 Expected return on assets 431 406 308 17 15 14 Net amortisation and deferral 111 76 45 3 32 Net periodic cost for the year 355 284 237 12 13 11 AstraZeneca Annual Report and 134 Form 20-F Information 2005 ADDITIONAL INFORMATION FOR US INVESTORS CONTINUED PENSION AND POST-RETIREMENT BENEFITS CONTINUED The weighted average allocation of pension and other post-retirement plan assets was as follows: 2005 2004 2003 % %% Equities 46.6 48.2 49.2 Bonds 37.5 35.6 48.8 Other 15.9 16.2 2.0 The benefits expected to be paid in the future are as follows: $m 2006 295 2007 306 2008 319 2009 332 2010 344 2011 2015 1,909 TAXATION 2004 2003 2005 restated restated Years ended 31 December $m $m $m Taxes on income from continuing operations Current tax expense Current year 1,747 1,349 902 Adjustment for prior years 112 171 26 Deferred tax expense Origination and reversal of temporary differences 265 355 17 Total taxation expense in the income statement 1,594 823 945 Restated in respect of SFAS 123 R The table below reconciles the UK statutory tax charge with the Groups actual charge on income from continuing operations.
2004 2003 2005 restated restated Years ended 31 December $m $m $m Income from continuing operations 5,478 3,774 3,094 Taxation charge at UK corporation tax rate of 30% for 2005 30% for 2004, 30% for 2003 1,644 1,132 928 Differences in effective overseas tax rates 147 2 41 Unrecognised deferred tax asset 25 25 Items not deductible for tax purposes 136 30 111 Items not chargeable for tax purposes 95 71 88 Adjustments in respect of prior periods 31 171 35 Exceptional items 124 Tax on income from continuing operations 1,594 823 945 Restated in respect of SFAS 123 R In 2005, claims amounting to $nil 2004 $nil, 2003 $95m for tax relief were made arising as a result of a restructuring of the AMI joint venture in 1998.
Under US GAAP, these reliefs are adjusted against the goodwill arising on the restructuring and included in other adjustments.
Additional Information for US Investors 135 SHAREHOLDERS EQUITY 2004 2003 2005 restated restated $m $m $m Total shareholders equity under IFRS 13,597 14,404 13,086 Adjustments to conform to US GAAP Purchase accounting adjustments including goodwill and intangibles Deemed acquisition of Astra Goodwill 13,504 15,130 14,342 Property, plant and equipment and intangible assets 5,229 6,988 7,661 Others 58 99 55 Capitalisation, less disposals and amortisation of interest 241 254 255 Deferred taxation On fair value of Astra 1,629 2,134 2,313 Others 492 618 555 In-licensed development intangibles 112 83 38 Pension and other post-retirement benefits 1,483 1,418 1,212 Financial instruments 18 22 57 Others 3 3 3 Shareholders equity in accordance with US GAAP 31,894 35,477 33,759 Restated in respect of SFAS 123 R ACQUIRED INTANGIBLE ASSETS AND GOODWILL Details of the carrying amounts of intangible assets and past and projected amortisation expenses are set out below.
2005 2004 2003 Gross Gross Gross carrying Accumulated carrying Accumulated carrying Accumulated amount amortisation amount amortisation amount amortisation $m $m $m $m $m $m Product rights 12,961 7,011 14,590 6,744 13,733 5,274 Marketing and distribution rights 1,494 1,043 1,729 1,043 1,659 831 Software 652 396 589 367 462 305 Others 437 310 460 360 421 329 Total 15,544 8,760 17,368 8,514 16,275 6,739 Aggregate amortisation expense $m For year ended 31 December 2005 1,287 For year ended 31 December 2004 1,316 For year ended 31 December 2003 1,245 Estimated amortisation expense For year ended 31 December 2006 1,275 For year ended 31 December 2007 1,187 For year ended 31 December 2008 1,187 For year ended 31 December 2009 1,187 For year ended 31 December 2010 1,187 The weighted average amortisation period in respect of each class of intangible asset is as follows: Product rights 13 years Marketing and distribution rights 16 years Software 4 years Other 8 years AstraZeneca Annual Report and 136 Form 20-F Information 2005 ACQUIRED INTANGIBLE ASSETS AND GOODWILL CONTINUED Goodwill The changes in the carrying amount of goodwill for the three years ended 31 December 2005 were as follows: $m Balance as at 1 January 2003 13,647 Acquired 1 Exchange movements 1,658 Balance as at 31 December 2003 15,306 Exchange movements 837 Balance as at 31 December 2004 16,143 Exchange movements 1,737 Balance as at 31 December 2005 14,406 US GAAP CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS 2005 2004 2003 For the years ended 31 December $m $m $m Cash flows from operating activities 6,919 4,842 3,416 Cash flows from investing activities Movement in short term investments and fixed deposits 1,922 862 771 New non-current investments 12 117 120 Disposal of property, plant and equipment 87 35 38 Acquisitions and disposals 355 80 Capital expenditure 942 1,183 1,515 Net cash outflows from investing activities 2,789 1,772 746 Net cash flow before financing 4,130 3,070 2,670 Cash flows from financing activities Equity dividends paid 1,717 1,378 1,222 Proceeds from issue of AstraZeneca PLC Ordinary Shares 143 102 47 Re-purchase of AstraZeneca PLC Ordinary Shares 3,001 2,212 1,154 Net increase in short term borrowings 3 2 New loans loans repaid 725 345 Net cash outflows from financing activities 4,572 2,761 2,674 Decrease increase in cash 442 309 4 Cash: At 1 January 915 581 524 Decrease increase in cash 442 309 4 Exchange movements 12 25 61 At 31 December 461 915 581 Interest paid was $32m in 2005 2004 $69m, 2003 $39m.
